MOTS-c is a mitochondrial-derived peptide that regulates metabolism and may produce some of the benefits of exercise. It's encoded within mitochondrial DNA, representing a novel class of signalling molecules.

Can MOTS-c replace exercise?

While MOTS-c is called an 'exercise mimetic' because it produces some metabolic benefits similar to exercise, it is unlikely to replicate all the diverse benefits of physical activity. Research is ongoing to understand its potential applications.

Is MOTS-c available for use?

MOTS-c is a research compound not approved for human use. It is not available through legitimate medical channels. Human clinical research is still in early stages.

Fact-checked by the Peptide Authority Editorial Board · Last reviewed: 1 February 2026

Share:X Post LinkedIn

Longevity & Anti-Ageing•Updated 2026-02-01•5 min read

What Is MOTS-c? Benefits, Research & Safety

A mitochondrial-derived peptide that regulates metabolic homeostasis and exercise adaptations, representing a novel class of signalling molecules.

Share:X Post LinkedIn

Also known as:

Mitochondrial ORF of the 12S rRNA Type-c

Mitochondrial-Derived Peptide

DAnimal/cell evidence onlyUK: Sold as 'research only' (UK)WADA: Sport status unclear

UK summary: Not a licensed UK medicine. Mitochondrial-derived peptide studied largely in preclinical animal and cell models. Sold by some online retailers as 'research only'. Likely captured by WADA's S0 non-approved substances category.

Quick Facts

Overview

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c) is a 16-amino acid peptide encoded within the mitochondrial genome. Discovered in 2015 by researchers at the University of Southern California led by Dr. Pinchas Cohen, MOTS-c represents a novel class of signalling molecules—mitochondrial-derived peptides (MDPs). Unlike most peptides which are encoded by nuclear DNA, MOTS-c is encoded by the mitochondrial 12S rRNA gene. This discovery challenged the traditional view that mitochondria primarily function as cellular powerhouses and revealed their role as signalling organelles. MOTS-c has been shown to regulate metabolic homeostasis, enhance insulin sensitivity, and promote the beneficial effects of exercise. Research suggests it acts as an exercise mimetic—producing some of the metabolic benefits of physical activity even without exercise. The peptide's levels appear to decline with age, and exercise increases its expression and secretion. This has generated significant interest in MOTS-c as a potential therapeutic for age-related metabolic dysfunction, type 2 diabetes, and as an exercise enhancement strategy. MOTS-c remains in early research stages and is not approved for therapeutic use.

Evidence standards summary

MOTS-c — evidence and risk at a glance

Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.

01Evidence snapshot

DAnimal/cell evidence onlyOverall grade against our evidence grading methodology.

Not a licensed UK medicine. Mitochondrial-derived peptide studied largely in preclinical animal and cell models. Sold by some online retailers as 'research only'. Likely captured by WADA's S0 non-approved substances category.

02Human evidence grade

ETheoretical / insufficientStrength of evidence from published human trials.

03Preclinical evidence grade

CLimited human evidenceAnimal-model and in-vitro evidence quality.

04Regulatory status

UK: Not licensed for human use. Research compound only.
EU: Not approved for therapeutic use.
Notes: MOTS-c is an early-stage research compound. Human clinical trials are in planning stages. Not available through legitimate medical channels.

05Approved medical uses

None in the UK or EU as a finished medicine. (Or: not yet documented; treat as absence rather than approval.)

06Unapproved / promotional claims

Reverses biological ageing at the mitochondrial level.
Acts as a complete substitute for cardio exercise.
Boosts metabolism and burns visceral fat without diet change.
Restores insulin sensitivity in type 2 diabetes.

07Common internet claims

Exercise in a vial — the mitochondrial peptide bodybuilders take.
Marketed as an anti-ageing breakthrough by longevity influencers.
Sold as research-only with dosing protocols copied from rodent studies.

08Claim vs evidence

Claim	Evidence	Human evidence?	Regulatory concern	Safer wording
“Reverses biological ageing”	E	No	High	Preclinical models show effects on mitochondrial metabolism; ageing-reversal claims in humans are not supported.
“Mimics the effects of exercise”	D	Limited	Moderate	Animal evidence suggests overlap with some exercise-related signalling; this does not equal substituting for exercise in humans.
“Boosts metabolism and burns fat”	D	No	High	Preclinical metabolic effects; human weight-loss claims are not established.
“Safe research peptide for personal use”	E	No	High	Long-term human safety is not established. 'Research only' labelling does not address UK regulatory questions about human-use marketing.

09Safety uncertainty score

High

Limited human safety data; meaningful uncertainty about rare or long-term effects.

10Known adverse signals

Injection site reactions reported anecdotally.
Unknown systemic effects from sustained AMPK activation in humans.
Theoretical interaction with metformin and other AMPK-modulating drugs.
Long-term consequences of exogenous mitochondrial peptide signalling are unstudied in people.

11Drug-interaction uncertainty

High

Interaction picture sparse; meaningful uncertainty when combined with other medicines.

12Anti-doping status

WADA: Sport status unclearWADA strict-liability framing applies.

13UK legal position

UK: Sold as 'research only' (UK)

Not licensed for human use. Research compound only.

Read the full UK legal guide → Are peptides legal in the UK?

14EU legal position

Not approved for therapeutic use.

15What this page cannot tell you

What dose of any online MOTS-c product is safe in humans — there is no licensed reference.
Whether grey-market vials actually contain the labelled peptide.
How chronic AMPK activation affects cancer risk, muscle wasting, or insulin signalling long-term.
Whether it stacks safely with metformin, GLP-1 agonists, or berberine.

16Last reviewed

Last reviewed: 1 February 2026

Next review due: 1 February 2027

Spotted an error or something out of date? Send a correction.

17Citation quality score

CLimited human evidenceQuality of the sources we cite, graded against the evidence grading methodology.

18Research gaps

No published Phase 2 or Phase 3 human trials with hard outcomes.
Pharmacokinetic data in humans is sparse.
Dose-response relationships for any human endpoint are unestablished.
Long-term safety entirely unknown.

19Safer alternatives / established care pathways

Structured aerobic exercise — the actual stimulus MOTS-c is claimed to mimic.
GP review for metformin if metabolic syndrome or pre-diabetes is the concern.
Licensed weight-management referral if obesity is the target outcome.

20Doctor discussion prompts

Questions to ask a qualified clinician

These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.

Is MOTS-c a licensed UK medicine?
What does the human evidence look like outside of preclinical mitochondrial research?
If I'm an athlete, what is the anti-doping position?
What licensed treatments exist for the metabolic outcomes I'm asking about?

Discovery & History

MOTS-c was discovered in 2015 by the laboratory of Dr. Pinchas Cohen at the University of Southern California (USC) Leonard Davis School of Gerontology. The discovery emerged from research into novel peptides encoded within the mitochondrial genome. Prior to this discovery, it was believed that mitochondrial DNA primarily encoded components of the electron transport chain and mitochondrial ribosomes. The identification of MOTS-c and other mitochondrial-derived peptides revealed that mitochondria could produce signalling molecules that regulate whole-body metabolism. The initial publication demonstrated that MOTS-c could prevent age-dependent and diet-induced obesity and insulin resistance in mice. The peptide appeared to work by promoting metabolic homeostasis and activating AMPK (AMP-activated protein kinase), a key metabolic sensor. Subsequent research showed that MOTS-c is secreted into circulation in response to exercise, suggesting it may mediate some of exercise's beneficial metabolic effects. Studies also revealed that MOTS-c levels decline with age, potentially contributing to age-related metabolic dysfunction. Research into MOTS-c and other mitochondrial-derived peptides continues, representing an exciting new area of metabolism and ageing research.

Mechanism of Action

MOTS-c exerts its metabolic effects through several mechanisms: **AMPK Activation** MOTS-c activates AMP-activated protein kinase (AMPK), a master regulator of cellular energy homeostasis. AMPK activation promotes glucose uptake, fatty acid oxidation, and mitochondrial biogenesis while inhibiting energy-consuming processes. **Nuclear Translocation** Remarkably, MOTS-c can translocate to the nucleus in response to metabolic stress, where it may directly regulate gene expression. This represents an unusual signalling mechanism for a mitochondrial-derived peptide. **Glucose Metabolism** MOTS-c enhances glucose uptake and utilisation by skeletal muscle, improving overall glucose homeostasis. It appears to promote the metabolic adaptations typically associated with exercise training. **Folate-Methionine Cycle Regulation** The peptide influences one-carbon metabolism through effects on the folate-methionine cycle, which is important for various biosynthetic and regulatory processes. **Exercise Mimetic Effects** MOTS-c reproduces some of the metabolic benefits of exercise, including improved insulin sensitivity and altered substrate utilisation. Exercise increases MOTS-c secretion, suggesting the peptide may mediate some exercise benefits. **Stress Response** MOTS-c appears to enhance cellular stress resistance, potentially contributing to the health-promoting effects of exercise and metabolic adaptation.

Researched Benefits

Based on preclinical and clinical research findings:

1
Improved insulin sensitivity in animal models
2
Prevention of diet-induced obesity in mice
3
Enhanced glucose metabolism and uptake
4
Activation of AMPK and metabolic regulation
5
Exercise mimetic effects on metabolism
6
Potential role in healthy ageing
7
Improved mitochondrial function

Claim vs Evidence

How popular claims about MOTS-c stack up against the current research, graded using our public evidence grading methodology.

Claim	Evidence	Human evidence?	Regulatory concern	Safer wording
“Reverses biological ageing”	E	No	High	Preclinical models show effects on mitochondrial metabolism; ageing-reversal claims in humans are not supported.
“Mimics the effects of exercise”	D	Limited	Moderate	Animal evidence suggests overlap with some exercise-related signalling; this does not equal substituting for exercise in humans.
“Boosts metabolism and burns fat”	D	No	High	Preclinical metabolic effects; human weight-loss claims are not established.
“Safe research peptide for personal use”	E	No	High	Long-term human safety is not established. 'Research only' labelling does not address UK regulatory questions about human-use marketing.

Theoretical Dosing & Protocols

⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.

Theoretical Dosage	Not established; animal studies use various weight-based doses
Frequency	Variable in research settings
Duration	Not established for human use
Notes	MOTS-c is in early research stages without established human protocols. Any information on dosing should be considered highly experimental. Human clinical trials are needed to determine appropriate use.

Administration Routes

Routes studied in research settings (educational only):

Subcutaneous injection (in animal research)
Intraperitoneal injection (animal models)

Half-Life	Stability
Limited human pharmacokinetic data available	Peptide stability data from research settings

Safety Profile & Known Risks

Commonly Reported Side Effects

Limited safety data in humans
Animal studies suggest generally well-tolerated

Rare Risks & Concerns

Unknown long-term effects
Effects on cancer cells uncertain
Metabolic effects in diabetics could require medication adjustment

Contraindications

Diabetes (potential blood glucose effects)
Pregnancy and breastfeeding
Active malignancy (effects unknown)
Children and adolescents

UK & EU Regulatory Context

🇬🇧 United Kingdom

Not licensed for human use. Research compound only.

🇪🇺 European Union

Not approved for therapeutic use.

MOTS-c is an early-stage research compound. Human clinical trials are in planning stages. Not available through legitimate medical channels.

Clinical Studies Summary

MOTS-c: A Mitochondrial-Derived Peptide Regulating Metabolic Homeostasis

Discovery paper demonstrating MOTS-c's role in metabolic regulation and prevention of obesity and insulin resistance in mice.

Cell Metab. 2015View on PubMed

Mitochondrial-Derived Peptides: Implication in the Therapy of Neurodegenerative Diseases.

Ethical Approval: Not applicable. Informed Consent: Not applicable.

Mol Neurobiol. 2025View on PubMed

MOTS-c in type 2 diabetes mellitus: From risk factors to cardiac complications and potential treatment.

The key role of MOTS-c in the major diabetes-related complications is specifically explored, with a special focus on its protective and therapeutic potential in diabetic cardiomyopathy.

Life Sci. 2025View on PubMed

Mitochondrial-derived peptides in cardiovascular disease: Novel insights and therapeutic opportunities.

We also provide insights into the current advancements in clinical research related to the utilization of MDPs in the treatment of CVDs. This review may provide valuable information with MDPs for CVD diagnosis and treatment.

J Adv Res. 2024View on PubMed

Mitochondrial-derived peptides: Antidiabetic functions and evolutionary perspectives.

MDPs attenuate disease pathology including Type 1 diabetes (T1D), Type 2 diabetes (T2D), gestational diabetes, Alzheimer's disease (AD), cardiovascular diseases, prostate cancer, and macular degeneration. The current review will focus on the MDP regulation of T2D, T1D, and gestational diabetes along with an emphasis on the evolutionary pressures for conservation of the amino acid sequences of MDPs.

Peptides. 2024View on PubMed

MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation.

Throughout this paper, we discussed the discovery and physiological function of mitochondrial-derived polypeptide MOTS-c, and the application of MOTS-c in the treatment of various diseases, such as aging, cardiovascular disease, insulin resistance, and inflammation.

Front Endocrinol (Lausanne). 2023View on PubMed

Registered Trials & Regulatory Status

Registered trials

Currently recruiting

Furthest phase

Phase 2

Approved product

Comparison of the Effects of General Anesthesia and Combined Spinal-Epidural Anesthesia on Ferroptosis, Humanin and MOTS-c Levels in Renal Transplantation

Status: Recruiting · 68 participants · University of Gaziantep

Conditions: Kidney Disease, End-Stage, Kidney Transplant, Kidney

No results postedNCT07678073

MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity

PHASE2

Status: Recruiting · 120 participants · Hudson Biotech

Conditions: Prediabetes, Insulin Resistance, Overweight/Obesity

No results postedNCT07505745

Platelet Reactivity, B-amyloid, MOTS-c and Mortality of Type II Diabetics With CAD

N/A

Status: Unknown · 120 participants · University of Athens

Conditions: Diabetes, Clopidogrel Resistance, Amyloid

No results postedNCT04027712

Adverse event reports (FDA FAERS)

Not applicable: no licensed product contains this peptide, so it is not reported through FAERS. This is an absence of surveillance, not evidence of safety.

Source: ClinicalTrials.gov and openFDA. Updated automatically.

Looking for MOTS-c?

Source research-grade MOTS-c from a trusted UK supplier — third-party tested with certificate of analysis.

View at Supplier

Frequently Asked Questions

Questions to ask a qualified clinician about MOTS-c